Core Insights - VolitionRx Limited is focusing on commercializing its Nu.Q® platform in the human diagnostics market, with ongoing discussions with over ten companies, whose combined market value exceeds $600 billion [2][25]. - The Total Addressable Market (TAM) for cancer and sepsis diagnostics is approximately $25 billion annually, presenting substantial revenue opportunities for the company and its partners [3][25]. - The company has successfully raised $4.2 million through direct registered offerings, primarily from existing shareholders, demonstrating strong insider support [4]. Cancer Diagnostics - Significant progress has been made in the commercialization of cancer diagnostics, with two major companies in active negotiations regarding Nu.Q® and Capture-Seq™ technologies [5]. - A pivotal lung cancer screening study in Taiwan is advancing, with the potential market for the Nu.Q® test exceeding $1 billion across Taiwan, the U.S., U.K., and France [6][25]. - The Nu.Q® NETs program has shown strong clinical promise, with two large-scale studies completed, indicating a strong mortality signal and a link to organ failure [7]. Commercialization Efforts - Licensing discussions for Nu.Q® NETs are progressing well, with several companies completing technology transfers [8]. - The company recorded its first revenue for the CE-Marked Nu.Q® NETs automated product in Europe, with nine hospitals placing orders [9]. - The expansion of the Nu.Q® Vet Cancer Test is a priority, with supply agreements in place with leading industry players [10]. Revenue Growth Strategies - Central lab automation is being implemented to enhance revenue growth and meet increasing demand for the Nu.Q® Vet Cancer Test [11][12]. - The Nu.Q® Discover platform has achieved commercial milestones, including the first sale of a High Throughput Synthetic Sepsis Model, with discussions ongoing for additional projects [13][14]. - A collaboration with a leading pharmaceutical company for a human clinical study utilizing Volition's biomarkers has been established, highlighting the value of biomarkers in drug development [15]. Future Outlook - The company aims to double revenue in the Nu.Q® Discover pillar in 2025, supported by a growing customer base [16]. - The focus for the remainder of 2025 is to secure multiple licensing agreements in the human diagnostics space, mirroring the successful strategy in the veterinary market [19]. - The company is committed to achieving commercial partnerships for human applications, which is a long-term mission [20].

Core Insights - Oryzon Genomics successfully completed a €30 million capital increase by issuing 12,765,958 new shares at €2.35 per share, reflecting a 15.44% discount to the 5-day volume-weighted average price and a 19.38% discount to the closing price prior to the offering [1][5] - The offering was significantly oversubscribed, with strong demand from investors, including a €15 million order from a US-based institutional investor [1][5] - The funds raised will support the advancement of clinical programs, particularly for vafidemstat in CNS disorders and the oncology and hematology pipeline, while also strengthening the company's financial position [2][6] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, focusing on CNS disorders and oncology [3] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [3] - Oryzon's team consists of highly qualified professionals located in Barcelona, Boston, and San Diego, with a strong platform for biomarker identification and target validation [3] Clinical Development Focus - Vafidemstat is being developed for aggression-related CNS disorders, including Borderline Personality Disorder (BPD) and Autism Spectrum Disorder (ASD), and has shown positive results in clinical trials [8] - Iadademstat is a selective inhibitor of LSD1, currently in various clinical trials for hematologic cancers, demonstrating safety and preliminary signs of antileukemic activity [4][7] - The company is expanding its clinical development efforts for both vafidemstat and iadademstat through collaborations and additional studies [7][8] Use of Proceeds - The capital raised will be allocated to advance clinical development for vafidemstat and iadademstat, support CMC activities, and prepare for Phase IIb-III trials [6] - Funds will also be used to strengthen the company's balance sheet for future partnership or M&A negotiations and cover general administrative expenses [6]

Core Insights - Oryzon Genomics has received a "Decision to grant" communication from the European Patent Office for its patent application related to vafidemstat, which is aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) using KDM1A inhibitors [1][2] - The European patent will remain in force until at least 2040, and a corresponding patent has already been granted in Japan for a related application concerning autism spectrum disorder [3][2] - These patent grants enhance Oryzon's intellectual property position and support the commercial potential of vafidemstat across various central nervous system (CNS) indications [4] Patent Developments - The European patent application EP20712563.4 covers methods of treating ADHD with vafidemstat, a compound currently in clinical development [1] - The Japanese patent application JP2022-514201 focuses on treating autism spectrum disorder and is the first in its patent family, with applications pending in other countries [3] - Oryzon's patent portfolio for vafidemstat includes additional families related to aggression, social withdrawal, and borderline personality disorder, with patents granted or allowed in multiple countries [7] Clinical Development - Vafidemstat is an oral, CNS-optimized LSD1 inhibitor that has shown promise in reducing cognitive impairment and neuroinflammation, with positive results in preclinical models and Phase II clinical trials [6][8] - The compound is advancing towards Phase III trials for borderline personality disorder and is also being evaluated for other CNS disorders, including schizophrenia and Kabuki Syndrome [8] - Oryzon has a robust clinical portfolio, with vafidemstat being Phase III-ready and another LSD1 inhibitor, iadademstat, in Phase II for oncology [5]

Core Insights - The company aims to generate sufficient clinical data in 2024 to convince major players in the diagnostic and liquid biopsy markets of the significance of its Nu.Q® platform in oncology and sepsis [1] - In 2025, the focus will shift to signing multiple licensing deals for human indications, with strong interest from large companies for potential out-licensing and supply agreements [2] Financial Highlights - The company reported revenue of $1.2 million for 2024, representing a 59% increase compared to the previous year [7] - Nu.Q® Vet revenue increased by 75%, while Nu.Q® Discover revenue rose by 40% compared to 2023 [7] - Operating expenses decreased by 23% year-over-year, with a 31% reduction in the second half of 2024 [7] - Cash and cash equivalents as of December 31, 2024, totaled approximately $3.3 million, with additional funding of $1.8 million received post-year-end [7] Product Development and Market Expansion - Approximately 120,000 Nu.Q® Vet Cancer Tests were sold in 2024, with the test now available in over 20 countries [6] - A range of independent studies demonstrating the value of the Nu.Q® platform in sepsis and oncology has been completed [6] - The company is advancing several commercial discussions with significant players in the human diagnostic and liquid biopsy markets, which are valued in the multibillion-dollar range [6] Leadership and Governance - The Board of Directors was strengthened with the appointment of Timothy Still as Chair and Dr. Ethel Rubin as Independent Director, both bringing significant experience in the diagnostic sector [6]

Core Insights - VolitionRx Limited will host a virtual investor event on April 9, 2025, featuring key executives discussing the company's progress and commercialization efforts [1][2] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics to improve early detection and monitoring of diseases [11][12] - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis [12] Market Opportunity - The Total Annual Accessible Market for lung cancer management is estimated at approximately $4 billion, presenting a significant revenue opportunity for Volition [3] - The potential market for liquid biopsy for multi-cancer early detection in the U.S. is valued at $20 billion, indicating a substantial growth opportunity for the company [5] Product Development - The Nu.Q® platform has shown promise in detecting common cancers with an overall AUC of 86% and low false positive rates, as reported in a paper currently under peer review [4] - The upcoming webinar will provide insights into the completion of large independent studies supporting the Nu.Q® platform's value in cancer detection [2] Leadership Team - Gael Forterre, Chief Commercial Officer, is focused on commercialization strategies and has extensive experience in scaling companies [6][7] - Dr. Andrew Retter, Chief Medical Officer, has a strong background in clinical trials and has published over 50 articles in peer-reviewed journals [8] - Dr. Jake Micallef, Chief Scientific Officer, is a founding scientist with expertise in diagnostics and has contributed to the development of Volition's Nucleosomics™ technology [9][10]

As filed with the Securities and Exchange Commission on October 18, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOXO Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 8731 85-1050265 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 729 N. Washington ...

As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. 333-274221 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOXO Technologies Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 85-1050265 (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on August 25, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOXO Technologies Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, c ...

As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOXO Technologies Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 6311 85-1050265 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 729 N. Washington Av ...